NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

FDA National Priority (CNPV) Voucher Program Submission
In parallel, SignPath submitted a justification package for review under the FDA’s new National Priority Voucher (CNPV) Program, which rewards development of therapies targeting urgent public health challenges, including conditions with severe unmet need such as glioblastoma.

>>“This is a significant opportunity for the program,” said Michelle Comas, Chief Operating Officer of SignPath Pharma. “The combination of Orphan Drug Designation, Fast Track submission, and the CNPV application positions LipoCurc™ for a potentially accelerated regulatory path as we prepare to meet with the FDA in early 2026.”

https://www.mywabashvalley.com/business/press-releases/ein-presswire/875676991/signpath-pharma-announces-orphan-drug-designation-and-fast-track-submission-for-lipocurc-in-glioblastoma/